# Are growth hormone peptides legal in Australia? Poisons Standard, TGA and WADA records Updated 2026-10-16. Australia's October 2026 Poisons Standard, instrument F2026L01327, gives somatropin, CJC-1295, ipamorelin, GHRP-2 (pralmorelin), GHRP-6, sermorelin and ibutamoren their own Schedule 4 entries, in a line check on 16 October 2026. The TGA names CJC-1295 among unapproved peptide products. The WADA 2026 List bans growth hormone and its releasing factors at all times. These are records of status, not advice. | | | | --- | --- | | Instrument | Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, [F2026L01327](https://www.legislation.gov.au/F2026L01327/latest/text) | | Check type | Schedule entries, Appendix D clause 5 and index checked against the instrument text, 16 October 2026 | | Somatropin | Schedule 4 and Appendix D clause 5; registered medicines on the ARTG | | Individual Schedule 4 entries | CJC-1295, ipamorelin, GHRP-2 (pralmorelin), GHRP-6, sermorelin, ibutamoren | | No individual entry found | Tesamorelin; class capture uncertain | | TGA | [Advisory of 13 April 2026](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products) names CJC-1295 among unapproved peptide products | | WADA 2026 List | S2.2.3 and S2.2.4, prohibited at all times; in force from 1 January 2026 ([WADA 2026 Prohibited List](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)) | | Records checked | 16 October 2026 | Three different rulebooks can describe one molecule, and each asks its own question. The first is a scheduling instrument. It sorts substances by how they must be supplied, for example only on prescription. The second is a medicines regulator. It records which products it has checked. The third is a sport's anti-doping code. It lists what an athlete may not use. So the same molecule can get three different answers. This page belongs to [the growth hormone peptides hub](/learn/growth-hormone-peptides). It sets out what each rulebook says about somatropin and the releasing peptides. It gives the date of each check and the limits of each check. It is a record, not legal advice. For your own position, ask a lawyer who reads the current instrument. ## Which growth hormone peptides are named in the Poisons Standard? Seven of these substances have their own entry: somatropin, CJC-1295, ipamorelin, GHRP-2, GHRP-6, sermorelin and ibutamoren. This comes from a line-by-line check of instrument F2026L01327 on 16 October 2026. The Poisons Standard is the national list that sorts medicines and poisons into groups called schedules. Schedule 4 is the prescription-only group. Schedule 4 and Appendix D clause 5 were both recorded for all of them except sermorelin. For sermorelin, Appendix D depends on broader class headings, and the check did not settle it. Tesamorelin and Modified GRF (1-29) had no individual entry found. The GHRP-2 entry uses both names, pralmorelin and GHRP-2. The CJC-1295 entry gives the CAS number 863288-34-0. A CAS number is a chemical's ID number in a global registry. So the exact identity of a product matters to whether the entry applies. [What Schedule 4 and Appendix D mean](/learn/peptides-and-australian-law/what-schedule-4-and-appendix-d-mean) explains both terms. The table below lists each row. The check read the individual entries, the class headings, Appendix D clause 5 and the index. It does not replace a lawyer's reading of the full instrument. ![One molecule in the centre linked to three books: Poisons Standard with a balance scale, Regulator with a magnifying glass, and Sport rules with a running track, showing three separate records for one substance.](/assets/content/edu-three-rulebooks.png) One molecule, three records: the October 2026 Poisons Standard (F2026L01327) schedules it, the TGA records which products it has assessed, and the WADA 2026 List bans growth hormone and its releasing factors at all times. Records checked 16 October 2026. ## What about names that are not in the Poisons Standard, such as tesamorelin? Tesamorelin had no entry of its own in the check on 16 October 2026. But the instrument also has broad class headings. They cover growth hormone releasing hormones, growth hormone releasing peptides and growth hormone secretagogues, which are compounds that make a gland release growth hormone. The instrument does not say which unnamed molecules belong to those classes. So whether a heading covers tesamorelin is left open here. A missing entry of its own is not permission. Tesamorelin is also an approved medicine in the United States, but that is a separate question from its Australian status. The check also found no entry of its own for Modified GRF (1-29). A product name alone does not prove what chemical is inside, or how a class heading applies to it. The hub does not state a class membership that the instrument leaves undefined. [The tesamorelin hub](/learn/tesamorelin) and [the CJC-1295 hub](/learn/cjc-1295) hold the matching records for each compound. ## Are any of these on the Australian Register of Therapeutic Goods? Yes, for somatropin. The Australian Register of Therapeutic Goods (ARTG) is the national database of approved health products. It lists a registered somatropin medicine, Genotropin, under [ARTG 78811](https://www.tga.gov.au/resources/artg/78811), checked on 16 October 2026. That entry names somatropin as an ingredient and gives the registration type as medicine. Each ARTG entry covers one product in one form. So this record does not show that any releasing peptide is registered. It also does not cover other products with the same ingredient. And a search that finds nothing does not prove a product is missing from the register. The [TGA ARTG search](https://www.tga.gov.au/resources/artg) is the source for product-level records. This page does not assume an ingredient is missing from the full register just because a search gives no exact match. ## What has the TGA said about peptide products? The TGA, Australia's medicines regulator, issued an advisory on 13 April 2026 ([TGA advisory, 13 April 2026](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products)). It says the TGA has not checked unapproved peptide products for safety, quality or effectiveness. Its examples include CJC-1295, along with BPC-157, GHK-Cu, TB-500 and retatrutide. The advisory also says a "research use only" label alone does not make supply lawful. Nor does it change a product's regulatory status. A separate TGA topic page, [Peptide products](https://www.tga.gov.au/resources/explore-topic/peptide-products), says how a product is regulated depends on two things: what it contains and what it is meant to do. The advisory also notes that state and territory laws may add their own controls. [The Australian peptide law guide](/learn/peptides-and-australian-law) and [the Western Australian law guide](/learn/peptides-perth/peptides-and-wa-law) set out those extra layers. ## What does the WADA list say about growth hormone and releasing peptides? The WADA 2026 Prohibited List bans both groups at all times, under section S2. It has applied since 1 January 2026. S2.2.3 covers growth hormone, its analogues and its fragments. Examples include lonapegsomatropin, somapacitan, somatrogon, AOD-9604 and hGH 176-191. S2.2.4 covers growth hormone releasing factors in three bullets. The first is GHRH and its analogues: CJC-1293, CJC-1295, sermorelin and tesamorelin. The second is growth hormone secretagogues and their mimetics, including ipamorelin and ibutamoren. The third is GH-releasing peptides, including GHRP-2 and GHRP-6. The examples are not a complete list. Using one group does not get around a rule written for the other, because the list names both. WADA publishes a new list each year. An athlete should check the current edition and ask the anti-doping body that runs their sport. That body, not this page, decides an athlete's status. Sports drug-testing labs study these peptides directly. A 2012 study in *Analytical Chemistry* looked at GHRP-1, -2, -4, -5, -6, hexarelin, alexamorelin and ipamorelin. It used rats and lab tests with human blood serum. The aim was to find breakdown products in urine that routine doping tests could look for. It is animal and lab work, and it states no athlete's status. [AOD-9604](/learn/aod-9604) is the named fragment example. Its hub reports what the human trial program measured. ## What does the FDA list say about GHRP-2 and GHRP-6? The US FDA keeps a list of bulk substances that compounding pharmacies, which mix medicines to order, have asked to use. The PDF, marked updated 21 March 2025, puts GHRP-6 in category 2. It puts GHRP-2 in both category 1 and category 2, for different routes into the body ([FDA 503B bulks list](https://www.fda.gov/media/94164/download), reopened 16 October 2026). So it is wrong to put every GHRP-2 entry in category 2. The categories describe how the FDA handles nominated substances. They are not approvals of finished medicines. The FDA's [safety-risk page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) gives the matching risk information. Neither FDA record decides a product's status in Australia. The category entries are records about raw substances put forward for compounding. They do not show Australian registration, and they do not approve a finished product. The FDA's own pages record the list and its stated limits. ## Comparison Poisons Standard entries from a line-by-line check of F2026L01327 on 16 October 2026. Schedule 4 means prescription-only. "No individual entry found" means the substance has no entry of its own. This is a record of entries, not legal advice and not a ranking. | Substance | Poisons Standard entry | Note from the check | | --- | --- | --- | | Somatropin | Schedule 4 and Appendix D clause 5 | Registered medicines exist on the ARTG | | CJC-1295 | Schedule 4 and Appendix D clause 5 | Entry specifies CAS 863288-34-0; ARTG product not confirmed | | Ipamorelin | Schedule 4 and Appendix D clause 5 | ARTG product not confirmed | | GHRP-2 (pralmorelin) | Schedule 4 and Appendix D clause 5 | Entry uses pralmorelin and GHRP-2; ARTG product not confirmed | | GHRP-6 | Schedule 4 and Appendix D clause 5 | ARTG product not confirmed | | Sermorelin | Schedule 4 | Appendix D clause 5 may apply through class headings; not settled | | Ibutamoren | Schedule 4 and Appendix D clause 5 | Not itself a peptide | | Tesamorelin | No individual entry found | Class capture uncertain | ## Frequently asked questions ### Does a research-use-only label change the status of a peptide in Australia? No. The TGA says a "research use only" label alone does not make supply lawful. It also does not change a product's regulatory status ([TGA advisory, 13 April 2026](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products)). ### Is a missing Poisons Standard entry permission? No. The instrument has class headings that can reach substances it does not name. It does not define which unnamed molecules sit inside them. Tesamorelin is an example: it has no entry of its own, and its class position is unsettled, in a line check of F2026L01327 on 16 October 2026. ### Are both growth hormone and its releasers banned in sport? Yes. The WADA 2026 List bans growth hormone at S2.2.3 and growth hormone releasing factors at S2.2.4, at all times. The anti-doping body for the sport decides an athlete's status. ## Citations - Thomas A, Delahaut P, Krug O, Schänzer W, Thevis M. Analytical Chemistry. 2012;84(23):10252-10259. DOI: 10.1021/ac302034w --- Canonical page: https://www.formlaboratories.com/learn/growth-hormone-peptides/are-growth-hormone-releasing-peptides-legal-in-australia Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide. - Site guide for agents: https://www.formlaboratories.com/llms.txt - Sitemap: https://www.formlaboratories.com/sitemap.xml - Full catalogue: https://www.formlaboratories.com/shop - Contact: hello@formlaboratories.com All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.